Scholarlink

Background <p>COVID-19, caused by SARS-CoV-2, has led to a global pandemic with varying clinical outcomes across different variants. C-reactive protein (CRP), an inflammatory marker, is commonly used to assess disease severity. This study aimed to compare serum CRP levels in hospitalized patients infected with the Omicron and Delta variants at Imam Khomeini Hospital, Urmia, in 2021.</p> Methods <p>A retrospective study was conducted on 673 hospitalized COVID-19 patients, aged 17 to 91 years. After applying the exclusion criteria, 64 patients were removed, and 609 patients remained for the final analysis. Data collected included demographic information, vaccination status, length of hospital stay, CRP levels, and disease outcomes. Serum CRP levels were measured, and statistical analyses were performed using SPSS version 27, including independent t-tests for group comparisons.</p> Results <p>The mean age of the patients was 54.34 ± 15.88 years, with 56.3% of participants being female. Among the patients, 65.5% had received the COVID-19 vaccine. The mean serum CRP level was 48.54 ± 32.37&#xa0;mg/L. A statistically significant difference in CRP levels was observed between vaccinated and unvaccinated patients, with unvaccinated patients having higher CRP levels. However, no significant difference in CRP levels was found between patients infected with the Omicron and Delta variants. CRP levels were significantly higher in patients who died compared to those who recovered. Additionally, female patients exhibited significantly higher CRP levels than male patients.</p> Conclusions <p>This study highlights the potential role of CRP as a marker for disease severity and prognosis in COVID-19 patients. While no significant difference was found between the Omicron and Delta variants in terms of CRP levels, vaccination status and patient outcomes were strongly associated with CRP levels. Further studies are needed to explore the role of CRP in predicting clinical outcomes and to investigate the mechanisms underlying gender differences in inflammatory responses to COVID-19.</p> Clinical trial number <p>Not applicable.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Determination and comparison of serum C-reactive protein levels in patients with Omicron and Delta strains of COVID-19 hospitalized in Imam Khomeini Hospital, Urmia, 2021

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月16日

查看全文
  • Keyvan Amini,
  • Babak Choobi Anzali,
  • Hamid Reza Mehryar,
  • Sara Abedi

摘要

Background

COVID-19, caused by SARS-CoV-2, has led to a global pandemic with varying clinical outcomes across different variants. C-reactive protein (CRP), an inflammatory marker, is commonly used to assess disease severity. This study aimed to compare serum CRP levels in hospitalized patients infected with the Omicron and Delta variants at Imam Khomeini Hospital, Urmia, in 2021.

Methods

A retrospective study was conducted on 673 hospitalized COVID-19 patients, aged 17 to 91 years. After applying the exclusion criteria, 64 patients were removed, and 609 patients remained for the final analysis. Data collected included demographic information, vaccination status, length of hospital stay, CRP levels, and disease outcomes. Serum CRP levels were measured, and statistical analyses were performed using SPSS version 27, including independent t-tests for group comparisons.

Results

The mean age of the patients was 54.34 ± 15.88 years, with 56.3% of participants being female. Among the patients, 65.5% had received the COVID-19 vaccine. The mean serum CRP level was 48.54 ± 32.37 mg/L. A statistically significant difference in CRP levels was observed between vaccinated and unvaccinated patients, with unvaccinated patients having higher CRP levels. However, no significant difference in CRP levels was found between patients infected with the Omicron and Delta variants. CRP levels were significantly higher in patients who died compared to those who recovered. Additionally, female patients exhibited significantly higher CRP levels than male patients.

Conclusions

This study highlights the potential role of CRP as a marker for disease severity and prognosis in COVID-19 patients. While no significant difference was found between the Omicron and Delta variants in terms of CRP levels, vaccination status and patient outcomes were strongly associated with CRP levels. Further studies are needed to explore the role of CRP in predicting clinical outcomes and to investigate the mechanisms underlying gender differences in inflammatory responses to COVID-19.

Clinical trial number

Not applicable.